SR-17018 Stats & Data

Reasoning and justification for harm-reduction updates (with sources): 1) SR‑17018 remains preclinical in the formal literature with no published human PK/PD; most information derives from animal/cellular studies and anecdotal reports. PubMed indexes mechanistic and animal studies but no human trials to date; therefore dose/time-course guidance is low‑confidence and must be framed as experimental. 2) Mechanistically, SR‑17018 shows atypical MOR signaling and persistent receptor phosphorylation reversible by naloxone; this implies effects can outlast subjective euphoria and that naloxone should still work in overdose. Users should avoid redosing too early and ensure naloxone is on hand. 3) In mice, chronic SR‑17018 produces less antinociceptive tolerance than morphine in some assays and can reverse morphine tolerance, which implies that a person’s tolerance to their usual opioid may fall during/after SR‑17018 use. Returning to a previous opioid dose can therefore be dangerous; dose much lower than usual and titrate. 4) The fall in opioid tolerance during abstinence or after detox is a known overdose risk; similar caution applies here when tolerance is reduced. 5) Combining any opioid with benzodiazepines, alcohol, or other CNS depressants increases risk of respiratory depression and fatal outcomes; include gabapentinoids given observed overdose risk when co‑prescribed with opioids. Avoid these combinations. 6) MAOIs with opioids carry documented hazardous and unpredictable interactions; avoid unless medically supervised. 7) Community reports show very wide dose ranges (tens to low hundreds of mg per dose) and frequent redosing every 6–12 h. This variability indicates batch potency differences and underscores the need for accurate weighing/volumetric dosing and conservative titration. 8) Several users report substantial tolerance reduction and muted effects of other opioids while on SR‑17018; after pausing SR‑17018, effects of other opioids may be unexpectedly strong. This supports start‑low/go‑slow if reintroducing a full agonist. 9) Do not assume absence of withdrawal with SR‑17018; some users report difficulty stopping after multi‑week use. Plan short durations and taper if needed. 10) Always treat SR‑17018 as a potent experimental opioid: avoid driving or hazardous work, use with a trusted sober person when first trialing, and keep naloxone available. General opioid overdose management guidance applies. 11) Because products are sourced from an unregulated market, expect variable identity/purity and scams; where possible, use drug checking and avoid unknown vendors. Community moderation posts flag recurrent scammers; treat supply chains skeptically. Additional consolidated guidance: • Start low, go slow; wait a full 6–12 h before redosing due to potentially persistent receptor effects. • If transitioning back to another opioid, begin at a fraction of prior dose (e.g., ≤25–50%) and titrate over days, watching for oversedation. • Avoid co‑administration with benzodiazepines, alcohol, Z‑drugs, GHB/GBL, or gabapentinoids; if already dependent on any, seek medical input before changes. • Naloxone should reverse SR‑17018‑related respiratory depression; multiple doses may be required. • No evidence that SR‑17018 is serotonergic; serotonin‑toxicity risk appears low relative to agents like tramadol/methadone, though data are sparse—exercise usual caution with serotonergic polypharmacy.